On June 10, Novo Nordisk rose 3.15% in regular trading, trading at $43.52/share, with trading volume of approximately $160 million. Multiple positive catalysts converged to drive the stock higher.

During the American Diabetes Association (ADA) Scientific Sessions, several clinical datasets were released that bolstered market sentiment. Notably, Novo Nordisk disclosed that oral Wegovy prescriptions have surpassed 3 million since its January launch, with over 80% of new prescriptions going to first-time GLP-1 users. The commercialization ramp significantly exceeded expectations, with prescriptions accelerating from 1 million in the first 12 weeks to an additional 2 million in the subsequent 10 weeks.

Additionally, Novo Nordisk announced that oral Wegovy has officially launched in the UAE, marking the first market outside the United States, with further international rollouts planned for the second half of the year. Separately, data showed semaglutide 2mg achieved comparable HbA1c reduction and superior weight loss versus tirzepatide in a one-year trial.

On the competitive front, Pfizer disclosed 20-week interim head-to-head data for danuglipron versus semaglutide. Novo Nordisk responded by noting the study was a small Phase 2 open-label trial with only 163 patients, emphasizing that comprehensive evaluation requires complete 48-week data and long-term cardiovascular evidence. The market reacted positively to Novo Nordisk's proactive stance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)